Alltrna

Executive Summary

Alltrna is pioneering the world's first tRNA platform, aiming to decode tRNA biology and develop therapeutics for thousands of diseases. Founded in 2021 and based in Cambridge, MA, the company is at a pre-clinical stage, leveraging its proprietary platform to engineer transfer RNA molecules for the treatment of genetic disorders, cancers, and other conditions. By harnessing the natural role of tRNAs in protein translation, Alltrna's approach offers a novel modality that could address mutations across multiple genes, potentially broadening the therapeutic landscape beyond conventional gene therapy. The company has attracted significant attention due to its platform's versatility and the large untapped market for tRNA-based drugs. As of 2026, Alltrna is expected to advance its lead programs toward IND-enabling studies, with key milestones including candidate selection and initial preclinical proof-of-concept data. The company's progress will depend on securing additional funding and establishing strategic partnerships to support its ambitious pipeline. With a strong scientific foundation and a clear vision, Alltrna represents a high-risk, high-reward opportunity in the RNA therapeutics space.

Upcoming Catalysts (preview)

• Q3 2026Lead Program Candidate Nomination70% success
• Q4 2026Preclinical Proof-of-Concept Data Release60% success
• Q1 2027Series B Financing or Major Partnership Announcement50% success